Galapagos NV (GLPG)
| Market Cap | 1.89B |
| Revenue (ttm) | 266.36M |
| Net Income (ttm) | 235.22M |
| Shares Out | 65.90M |
| EPS (ttm) | 3.44 |
| PE Ratio | n/a |
| Forward PE | 81.30 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 167,619 |
| Open | 28.75 |
| Previous Close | 28.77 |
| Day's Range | 28.33 - 28.75 |
| 52-Week Range | 28.35 - 45.21 |
| Beta | 0.02 |
| Analysts | Hold |
| Price Target | 43.80 (+52.99%) |
| Earnings Date | May 6, 2024 |
About GLPG
Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T ... [Read more]
Analyst Forecast
According to 5 analysts, the average rating for GLPG stock is "Hold." The 12-month stock price forecast is $43.8, which is an increase of 52.99% from the latest price.
News
Galapagos showcases innovative approach in hematological cancer care with clinical and translational data presentations at EBMT congress 2024
Two oral presentations and one poster on encore preliminary data from Phase 1/2 CD19 CAR-T studies in non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL) / Richter transformation (RT)
Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders' Meetings
Mechelen, Belgium; 28 March 2024, 21.01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) today publishes its annual report for the financial year 2023 and announces its Annual and E...
Galapagos appoints Andrew Dickinson as Non-Executive Non-Independent Director to its Board
Mechelen, Belgium; 26 March 2024, 21:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that during its meeting of 26 March 2024, the Board of Directors appointed Mr. Dickinson as Non-Exec...
Galapagos announces full year 2023 results and outlook for 2024
Full year 2023 key financials : Group net revenues of €783.5 million, including Jyseleca® net sales of €112.3 million Cash and current financial investments of €3.7 billion on 31 December 2023 Operati...
Galapagos presents at EBMT-EHA annual meeting 2024
Showcases meaningful advances in decentralized CAR T-cell manufacturing and presents translational and clinical data from ongoing Phase 1/2 CD19 CAR-T studies
Galapagos completes transaction to transfer Jyseleca® business to Alfasigma
Mechelen, Belgium; 31 January 2024, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced the successful completion of the transaction to transfer its Jyseleca® (filgotinib) business to Al...
Galapagos enters into strategic collaboration agreement with Thermo Fisher Scientific to further expand its decentralized CAR-T manufacturing network in the U.S.
Mechelen, Belgium; 4 January 2024, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that it has entered into a strategic collaboration agreement with Thermo Fisher Scientific, Inc. (N...
Galapagos establishes strategic collaboration with BridGene Biosciences to expand small molecule drug discovery in oncology
Mechelen, Belgium; 3 January 2024, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that it has entered into a strategic collaboration and licensing agreement with BridGene Bioscience...
BridGene Biosciences Announces Strategic Collaboration with Galapagos to Discover Small Molecule Drugs for Oncology Targets
BridGene Eligible to Receive More Than $700 Million in Potential Upfront and Milestone Payments SAN JOSE, Calif. , Jan. 3, 2024 /PRNewswire/ -- BridGene Biosciences, Inc., a leader in the discovery of...
Galapagos signs agreement to transfer Jyseleca® business to Alfasigma
Mechelen, Belgium; 02 January 2024, 07:00 CET; Galapagos NV (Euronext & NASDAQ: GLPG) and Alfasigma S.p.A. today announced that they have signed an agreement to transfer Galapagos' Jyseleca® (filgotin...
Galapagos announces start of PAPILIO-1 Phase 1/2 multiple myeloma study of point-of-care manufactured BCMA CAR-T candidate, GLPG5301
Mechelen, Belgium; 19 December 2023, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that the first patient has been dosed in PAPILIO-1, the Phase 1/2 study to evaluate the safety, e...
Galapagos presents new encouraging data at ASH 2023 from ongoing CD19 CAR-T studies with GLPG5201 and GLPG5101
Galapagos to host a Key Opinion Leader (KOL) event with live webcast on Sunday, 10 December 2023 at 11:00 am PT/20:00 CET
Galapagos to Host KOL Event on December 10, 2023, at 11:00 AM PST to discuss new data presented at ASH 2023
Mechelen, Belgium; 6 December 2023, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that it will host a Key Opinion Leader (KOL) event during the 65th ASH Annual Meeting & Exposition...
Landmark Bio Signs Multi-Year Agreement to Manufacture Galapagos' Oncology CAR-T Cell Therapy Clinical Programs at the Point-of-Care
Landmark Bio will serve as strategic point-of-care manufacturing partner for Galapagos' CAR-T product candidates in the Boston area WATERTOWN, Mass. , Nov. 6, 2023 /PRNewswire/ -- Landmark Bio, a coll...
Galapagos reports third quarter 2023 results and releases new encouraging data from CAR-T studies for presentation at ASH 2023
Webcast presentation tomorrow, 3 November 2023, at 1 3 : 00 CET / 8 :00 am ET, www.glpg.com
Galapagos concludes strategic evaluation and signs letter of intent to transfer Jyseleca® business to Alfasigma
Mechelen, Belgium; 30 October 2023, 21:01 CET; regulated information – inside information – Galapagos NV (Euronext & NASDAQ: GLPG) and Alfasigma S.p.A. today announced that they have signed a letter o...
Galapagos appoints Simon Sturge to its Board of Directors
Mechelen, Belgium; 1 9 September 2023, 22:01 CET ; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that during its meeting of 19 September 2023 , the Board of Directors appointed Mr. Simon Stur...
Galapagos announces start of Phase 2 study with selective TYK2 inhibitor, GLPG3667, in patients with active systemic lupus erythematosus
Mechelen, Belgium; 28 August 2023 , 22.01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that the first patient was randomized in GALACELA, a Phase 2 systemic lupus erythematosus (SLE) tr...
Galapagos announces first half-year 2023 financial results
Webcast presentation tomorrow, 4 August 2023, at 14:00 CET / 8:00 am ET, www.glpg.com
Galapagos appoints Thad Huston as Chief Financial Officer and Chief Operating Officer
Mechelen, Belgium; 15 June 2023, 22:01 CET ; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) today announced the appointment of T had Huston as Chief Financial Officer (C F O) and Chief...
Galapagos appoints Dr. Susanne Schaffert as non-executive independent Director to its Board
Mechelen, Belgium; 12 June 2023, 22:01 CET ; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that during its meeting of 12 June 2023 , the Board of Directors co-opted Dr. Susanne S chaffert as ...
Galapagos to showcase CAR-T point-of-care manufacturing and initial Phase 1/2 CLL data with CD19 CAR-T candidate, GLPG5201, at the EHA 2023 congress
Mechelen, Belgium ; 5 June 202 3 , 22 : 01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that it will feature the CAR-T point-of-care manufacturing platform and will present previously d...
Galapagos announces start of Phase 2 study with selective TYK2 inhibitor, GLPG3667, in patients with dermatomyositis
Mechelen , Belgium; 2 3 May 2023, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that the first patient was dosed in GALARISSO, the Phase 2 dermatomyositis (DM) trial with GLPG3667.
Galapagos demonstrates commitment to immunology with new data in rheumatoid arthritis at EULAR 2023
Mechelen , Belgium; 22 May 2023, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) will present a broad range of abstracts, including analysis from randomized controlled trials (RCTs) and real-world e...
Galapagos creates new subscription right plans
Mechelen, Belgium ; 5 M ay 2023 , 22 : 01 CET; regulated information – Galapagos NV (Euronext & NASDAQ : GLPG) announced today that its B oard of D irectors created 1 , 975 , 000 subscription rights...